Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05634694 | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients | unknown | — | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Nov 25, 2022 |
| clinicaltrials |
| NCT05626127 | MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma | unknown | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05580328 | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | unknown | N/A | 10 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT05613465 | Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo | unknown | N/A | 100 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05596370 | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer | unknown | — | 150 | Seoul National University HospitalOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05604716 | Cross-sectional Follow-up on Digestive and Social Functions of SPN | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05580887 | Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients | unknown | — | 35 | Moscow Clinical Scientific CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05571956 | Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples | unknown | N/A | 50 | Ajou University School of MedicineOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04856761 | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | unknown | — | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05493878 | ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer | unknown | — | 128 | Assiut UniversityOTHER | 0 | Aug 9, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04258072 | Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | unknown | Phase 1 | 24 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05400681 | Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer(LIPAC) | unknown | — | 200 | Sonke DetlefsenOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05253313 | Magnetic Resonance Imaging for Better Selection of Pancreatic Cancer Patients for Surgery: A Randomized Clinical Trial(MAGIPAC) | unknown | N/A | 200 | University of AarhusOTHER | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05275985 | 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma | unknown | N/A | 80 | Peking Union Medical College HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04812808 | Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma(BAZE) | unknown | N/A | 10 | Hôpital FribourgeoisOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05201729 | Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer | unknown | — | 30 | Ruijin HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05192044 | Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT | unknown | N/A | 40 | National Cancer Institute, EgyptOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03978702 | Evaluation of the Impact of Pancreatectomy on Systemic Immunity(IMMUNOPANC) | unknown | N/A | 40 | Institut Paoli-CalmettesOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05168254 | Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer | unknown | — | 50 | Ruijin HospitalOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT02944006 | Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling | unknown | — | 29 | Seoul National University HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT02232932 | Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma(TRANSPHIL) | unknown | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT05064852 | A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma | unknown | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 0 | Oct 1, 2021 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04779788 | I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma | unknown | N/A | 100 | Xuzhou Central HospitalOTHER | 1 | Jul 14, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2022source: clinicaltrials